Table 1.

Attributes and levels used for the DCE

Attribute	Level used in design		Level used in modelb
Average overall survivala & Remission period	1 year survival	3 months remission	1	Short
		9 months remission	1	Long
	3 years survival	9 months remission	3	Short
		2 years 3 months remission	3	Long
	5 years survival	1 year 3 months remission	5	Short
		3 years 9 months remission	5	Long
	7 years survival	1 year 9 months remission	7	Short
		5 years 3 months remission	7	Long
	9 years survival	2 years 3 months remission	9	Short
		6 years 9 months remission	9	Long
Side effects	Mild or moderate	None	0
		20% risk, lasting up to 2 months	20
		20% risk, lasting longer than 2 months	20
		40% risk, lasting up to 2 months	40
		40% risk, lasting longer than 2 months	40
		60% risk, lasting up to 2 months	60
		60% risk, lasting longer than 2 months	60
	Severe	None	None
		5% risk, lasting up to 2 months	Some
		5% risk, lasting longer than 2 months	Some
		10% risk, lasting up to 2 months	Some
		10% risk, lasting longer than 2 months	Some
Mode & Frequency of administration	Oral	Daily	Oral
		Weekly	Oral
	Subcutaneous (SC)	2–3 times per week	SC - high
		Weekly	SC - high
		Fortnightly	SC - low
		Monthly	SC - low
	Intravenous (IV)	2–3 times per week	IV - high
		Weekly	IV - high
		Fortnightly	IV – low
		Monthly	IV - low
Annual out of pocket costsc	$0		0
	$500		5
	$1500		15
	$3000		30
	$5000		50

^aAverage overall survival was treated as a quantitative variable in the model

^bincludes regrouping of levels for certain attributes

^cDivided by 100 for modelling purposes